Tu Y H, Stiles M L, Allen L V, Olsen K M, Barton C I, Greenwood R B
University of Oklahoma Health Sciences Center, College of Pharmacy, Oklahoma City 73190.
Am J Hosp Pharm. 1988 May;45(5):1092-9.
The stability of reconstituted amoxicillin trihydrate-potassium clavulanate oral suspension both in original containers and pre-packaged in commercially available oral syringes stored at various temperatures was determined. Amoxicillin trihydrate 125 mg/5 mL-potassium clavulanate 31.25 mg/5 mL and amoxicillin trihydrate 250 mg/5 mL-potassium clavulanate 62.5 mg/5 mL were reconstituted according to the manufacturer's instructions. The reconstituted suspensions in the original containers and in five brands of oral syringes were stored at 5 degrees C and 25 degrees C and -10 degrees C, 5 degrees C, and 25 degrees C, respectively, for 0, 2, 4, 7, and 14 days. The concentrations of amoxicillin trihydrate and potassium clavulanate remaining after storage were assayed in triplicate by reverse-phase high-performance liquid chromatography, using a stability-indicating method. An F statistic was calculated to determine whether different syringe brands had significantly different effects on drug stability. Amoxicillin trihydrate was stable for at least 10 days in the original containers and all types of oral syringes at 5 degrees C. However, potassium clavulanate was stable for 11.1 days in original containers and less than 5 days in all types of oral syringes at 5 degrees C. The effect of syringe brand on the stability of drugs over time at specific storage conditions and temperature was significant for potassium clavulanate at 5 degrees C and for both amoxicillin trihydrate and potassium clavulanate at 25 degrees C. The manufacturer's guidelines for storage of reconstituted amoxicillin trihydrate-potassium clavulanate oral suspension in the original containers should not be applied to dosages repackaged in unit dose oral syringes.
测定了复溶后的三水合阿莫西林-克拉维酸钾口服混悬液在原包装容器以及预先包装在市售口服注射器中于不同温度下储存时的稳定性。按照制造商的说明复溶了125 mg/5 mL三水合阿莫西林-31.25 mg/5 mL克拉维酸钾以及250 mg/5 mL三水合阿莫西林-62.5 mg/5 mL。将原包装容器中的以及五个品牌口服注射器中的复溶混悬液分别储存在5℃和25℃以及-10℃、5℃和25℃下,储存0、2、4、7和14天。储存后剩余的三水合阿莫西林和克拉维酸钾浓度采用稳定性指示方法通过反相高效液相色谱法进行三次重复测定。计算F统计量以确定不同注射器品牌对药物稳定性是否有显著不同的影响。三水合阿莫西林在5℃下于原包装容器和所有类型的口服注射器中至少稳定10天。然而,克拉维酸钾在5℃下于原包装容器中稳定11.1天,在所有类型的口服注射器中稳定时间少于5天。在特定储存条件和温度下,注射器品牌对药物稳定性随时间的影响对于5℃下的克拉维酸钾以及25℃下的三水合阿莫西林和克拉维酸钾均具有显著性。制造商关于复溶后的三水合阿莫西林-克拉维酸钾口服混悬液在原包装容器中储存的指南不适用于单位剂量口服注射器中重新包装的剂量。